- Home
- LBTYA vs INDV Comparison
LBTYA vs INDV Comparison
Compare LBTYA & INDV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LBTYA | INDV |
|---|---|---|
| Founded | 2004 | N/A |
| Country | Bermuda | United States |
| Employees | N/A | N/A |
| Industry | Cable & Other Pay Television Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0B | 4.7B |
| IPO Year | 2013 | 2014 |
Fundamental Metrics
Financial Performance| Metric | LBTYA | INDV |
|---|---|---|
| Price | $10.78 | $36.09 |
| Analyst Decision | Hold | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $13.72 | N/A |
| AVG Volume (30 Days) | 2.3M | ★ 2.5M |
| Earning Date | 05-01-2026 | 06-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 8100.00 |
| EPS | 0.96 | ★ 1.67 |
| Revenue | ★ $11,541,500,000.00 | $1,239,000,000.00 |
| Revenue This Year | $15.41 | N/A |
| Revenue Next Year | $3.03 | N/A |
| P/E Ratio | ★ $11.24 | $21.54 |
| Revenue Growth | N/A | ★ 4.29 |
| 52 Week Low | $9.43 | $22.22 |
| 52 Week High | $13.52 | $42.81 |
Technical Indicators
Market Signals| Indicator | LBTYA | INDV |
|---|---|---|
| Relative Strength Index (RSI) | 56.14 | 33.04 |
| Support Level | $10.47 | $35.49 |
| Resistance Level | $11.04 | $38.08 |
| Average True Range (ATR) | 0.25 | 1.15 |
| MACD | 0.07 | -0.31 |
| Stochastic Oscillator | 87.73 | 11.45 |
Price Performance
Historical ComparisonAbout LBTYA Liberty Global Ltd.
Liberty Global is a holding company with interests in European telecom companies in the UK, the Netherlands, Belgium, Ireland, and Slovakia. Liberty owns the main cable network in each of these geographies and has pursued a strategy since 2016 to merge or partner with mobile network operators to be able to offer converged services. Liberty also owns minority stakes in other media, entertainment, and cloud companies.
About INDV Indivior PLC
Indivior Pharmaceuticals Inc is a specialty pharmaceutical company singularly focused on delivering evidence-based treatment and advancing understanding of opioid use disorder (OUD) as a chronic but treatable brain disease. The company derives revenues from customers through the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence and related disorders. The company's products include: Sublocade (buprenorphine extended-release monthly injection), and Suboxone (buprenorphine and naloxone sublingual film).